P3781
HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive AdultsA Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected SubjectsPENTA Fosamprenavir StudyComparative Tolerability of Protease Inhibitors48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV InfectionKALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 WeeksPharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects (2010-07-31)An Interaction Study to Assess Drug Levels in Healthy Adult Subjects (2008-10-31)Lexiva for the Treatment of LPR
P4844
P769
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialAntiviral drug allergy.Effect of fosamprenavir-ritonavir on the pharmacokinetics of dolutegravir in healthy subjectsPost-licensing safety of fosamprenavir in HIV-infected children in Europe.Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.Pharmacokinetic Interaction Between Maraviroc And Fosamprenavir/Ritonavir In Healthy Subjects (2010-07-31)
P921
Q61921056-99BC97A7-A2CC-4670-8DE3-F930B2EEAB86Q61934733-1A7117CD-C4FA-4164-BF25-0C7204F3B002Q61938009-01662995-B5B5-4BB0-AED7-F58514241158Q61967393-E1252C41-F85C-42CE-8271-F7A3826883CCQ62110036-86C40DEA-D80E-4BD5-B7C7-9ACC510D3CE1Q62110605-2463864B-66C0-4CE3-8BDC-2FEB2899069AQ86171791-063D71F9-61A0-4BAE-A34D-268E7601C523Q86175120-2A7B6A95-001A-4063-9FD3-DF34E43AB498Q94234884-5CB8F625-C148-438E-9802-437D321B286C
P4844
Q28256092-A4BA4A21-BF9B-4831-8C63-78E8F0C75E80Q34075812-311429BB-F6ED-4162-A6DC-1985021F14A8Q34596882-CB4CCF50-7641-4C9B-A0AD-76926566A87AQ34692768-7E55C1EA-C44C-4098-9F97-2DDE588ED5B2Q35672530-6A5A31DF-2513-4051-B579-BD8E1405741BQ36930395-DFDE01C8-A381-4A91-ABE1-1EEB0FF0E266Q37439512-491B0F06-6C32-41EF-A2C9-8DF84FDBACC3Q50637890-DFFA2867-CFC4-4D1B-80A8-77461E7D63FBQ86171791-FA5A5A85-49CE-43DE-BDDA-F36E196E4D2F
P921
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Fosamprenavir
@de
Fosamprenavir
@es
Fosamprenavir
@nl
Fosamprenavir
@sh
Fosamprenavir
@sr
fosamprenavir
@en
fosamprenavir
@fr
fosamprenavir
@nn
Фосампренавір
@uk
фосампреновир
@ru
type
label
Fosamprenavir
@de
Fosamprenavir
@es
Fosamprenavir
@nl
Fosamprenavir
@sh
Fosamprenavir
@sr
fosamprenavir
@en
fosamprenavir
@fr
fosamprenavir
@nn
Фосампренавір
@uk
фосампреновир
@ru
altLabel
FOS-APV
@en
Fosamprenavir
@en
prefLabel
Fosamprenavir
@de
Fosamprenavir
@es
Fosamprenavir
@nl
Fosamprenavir
@sh
Fosamprenavir
@sr
fosamprenavir
@en
fosamprenavir
@fr
fosamprenavir
@nn
Фосампренавір
@uk
фосампреновир
@ru